Related Experiment Video
Updated: Mar 18, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
NG25 Enhances Anti-Tumor Immunity in KRAS-Mutant Colorectal Cancer
Qi Xiang1, Zhigang Mao2, Qizhao Ma1
1West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Purpose:
The poor prognosis of KRAS-mutant colorectal cancer is attributed to its immunosuppressive tumor microenvironment and the lack of effective targeted therapies. Transforming growth factor-β-activated kinase 1 (TAK1), serving as a critical upstream regulator of both the NF-κB and MAPK signaling pathways, promotes tumor progression through its aberrant activation. In this study, we aimed to investigate the anti-tumor and immunomodulatory effects of the TAK1 inhibitor NG25 in KRAS-mutant colorectal cancer, focusing on its impact on T cell differentiation, PD-L1 expression, and tumor immune microenvironment remodeling.
Methods:
The anti-tumor and immune-enhancing effects of NG25 were evaluated through an in vitro tumor cell-lymphocyte co-culture system, and the orthotopic colorectal cancer models in both immunodeficient Balb/c nude mice and immunocompetent Balb/c mice.
Results:
NG25 significantly suppressed the tumor progression in immunocompetent Balb/c mice, while concurrently increasing the spleen and thymus indices and promoting the proliferation of T and B lymphocytes. In tumor microenvironment, NG25 treatment could promote CD8⁺ T cell infiltration and increase the proportion of CD3⁺CD8⁺ T cell subsets. Mechanistic studies revealed that NG25 downregulates PD-L1 expression on both KRAS-mutant tumor cells and T cells through inhibiting TAK1/NF-κB axis. However, this regulatory effect was absent in KRAS wild-type tumor cells.
Conclusion:
NG25 blocks the NF-κB signaling pathway by targeting TAK1, remodels the immunosuppressive microenvironment of KRAS-mutated colorectal cancer, reduces PD-1 expression and enhances the anti-tumor effect of CD8⁺ T cells. This study provides a theoretical basis for TAK1-targeted therapy and offers a new strategy for immunotherapy of KRAS-mutated colorectal cancer.
Insights
The TAK1 inhibitor NG25 effectively combats KRAS-mutant colorectal cancer by remodeling the immunosuppressive tumor microenvironment. This targeted therapy enhances CD8+ T cell activity and PD-L1 downregulation, offering a promising new strategy for cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- KRAS-mutant colorectal cancer has a poor prognosis due to an immunosuppressive tumor microenvironment and limited targeted therapies.
- Transforming growth factor-β-activated kinase 1 (TAK1) is a key regulator of NF-κB and MAPK pathways, promoting tumor progression when aberrantly activated.
Purpose of the Study:
- To investigate the anti-tumor and immunomodulatory effects of the TAK1 inhibitor NG25 in KRAS-mutant colorectal cancer.
- To assess NG25's impact on T cell differentiation, PD-L1 expression, and tumor immune microenvironment remodeling.
Main Methods:
- In vitro tumor cell-lymphocyte co-culture system.
- Orthotopic colorectal cancer models in immunodeficient and immunocompetent mice.
- Evaluation of spleen and thymus indices, lymphocyte proliferation, and T cell subset proportions.
- Mechanistic studies on TAK1/NF-κB signaling and PD-L1 expression.
Main Results:
- NG25 suppressed tumor progression in immunocompetent mice, increasing spleen/thymus indices and promoting T and B lymphocyte proliferation.
- NG25 treatment promoted CD8+ T cell infiltration and increased CD3+CD8+ T cell subsets within the tumor microenvironment.
- NG25 downregulated PD-L1 expression on KRAS-mutant tumor cells and T cells by inhibiting the TAK1/NF-κB axis, an effect not observed in KRAS wild-type cells.
Conclusions:
- NG25 targets TAK1 to block the NF-κB pathway, remodeling the immunosuppressive microenvironment in KRAS-mutated colorectal cancer.
- NG25 reduces PD-1 expression and enhances anti-tumor CD8+ T cell activity.
- This study provides a rationale for TAK1-targeted therapy and a novel immunotherapy strategy for KRAS-mutated colorectal cancer.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...